Monomethyl Auristatin E (MMAE)
Monomethylauristatin E
Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer. MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.
Organism species: Pan-species (General)
- Conjugated small molecules CPX165Ge21 OVA Conjugated Monomethyl Auristatin E (MMAE) In Stock
- Customized Service n/a Monoclonal Antibody to Monomethyl Auristatin E (MMAE) Monoclonal Antibody Customized Service Offer
- Customized Service n/a Polyclonal Antibody to Monomethyl Auristatin E (MMAE) Polyclonal Antibody Customized Service Offer
- Customized Service n/a CLIA Kit for Monomethyl Auristatin E (MMAE) CLIA Kit Customized Service Offer
- Customized Service n/a ELISA Kit for Monomethyl Auristatin E (MMAE) ELISA Kit Customized Service Offer